The phase 3 trial Check-Mate 816 evaluated the efficacy and safety of neoadjuvant Nivolumab plus platinum doublet chemotherapy (three cycles) as compared with platinum doublet chemotherapy alone (three cycles), before definitive surgery, in patients with resectable NSCLC, stage IB (≥4 cm) to IIIA (AJCC 7th edition), without known ALK translocations or EGFR mutations [121]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.